Advertisement
DALLAS, Jan. 28, 2015 /PRNewswire-iReach/ -- The report "Pertussis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.
Photo - http://photos.prnewswire.com/prnh/20150128/171899
Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Whooping cough (pertussis) is a highly contagious respiratory tract infection. The classic symptoms of pertussis are a paroxysmal cough, inspiratory whoop and fainting or vomiting after coughing. Worldwide, there are about 20 to 40 million cases of and 400,000 deaths from pertussis each year. It is most dangerous for children under 1 year old, especially if they are unvaccinated or under-vaccinated.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269542 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Pertussis – Pipeline Review, H1 2015 report include Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., Bharat Biotech International Limited, Biological E. Limited, Daiichi Sankyo Company, Limited, DBV Technologies S.A., Green Cross Corporation, Indian Immunologicals Limited, LG Life Sciences, Ltd., NanoBio Corporation, Novartis AG, Panacea Biotec Limited, Sanofi, Sanofi Pasteur SA, Serum Institute of India Limited, Sinovac Biotech Ltd., Synthetic Biologics, Inc., Takeda Pharmaceutical Company Limited, Zydus Cadila Healthcare Limited.
Scope of Pertussis – Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Pertussis; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269542 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases:
Reasons to buy
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
Advertisement
Photo - http://photos.prnewswire.com/prnh/20150128/171899
Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Whooping cough (pertussis) is a highly contagious respiratory tract infection. The classic symptoms of pertussis are a paroxysmal cough, inspiratory whoop and fainting or vomiting after coughing. Worldwide, there are about 20 to 40 million cases of and 400,000 deaths from pertussis each year. It is most dangerous for children under 1 year old, especially if they are unvaccinated or under-vaccinated.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269542 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Pertussis – Pipeline Review, H1 2015 report include Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., Bharat Biotech International Limited, Biological E. Limited, Daiichi Sankyo Company, Limited, DBV Technologies S.A., Green Cross Corporation, Indian Immunologicals Limited, LG Life Sciences, Ltd., NanoBio Corporation, Novartis AG, Panacea Biotec Limited, Sanofi, Sanofi Pasteur SA, Serum Institute of India Limited, Sinovac Biotech Ltd., Synthetic Biologics, Inc., Takeda Pharmaceutical Company Limited, Zydus Cadila Healthcare Limited.
Scope of Pertussis – Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Pertussis; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269542 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases:
- Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program
- Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
- Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
- Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
- Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic
- Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
- Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
- Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
- Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough
- Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companiesIdentify and understand important and diverse types of therapeutics under development for Pertussis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
